Transcatheter Arterial Embolization Therapy for a Massive Polycystic Liver in Autosomal Dominant Polycystic Kidney Disease Patients

Polycystic liver is the most common extra-renal manifestation associated with autosomal dominant polycystic kidney disease (ADPKD), comprising up to 80% of all features. Patients with polycystic liver often suffer from abdominal discomfort, dyspepsia, or dyspnea; however, there have been few ways to relieve their symptoms effectively and safely. Therefore, we tried transcatheter arterial embolization (TAE), which has been used in treating hepatocellular carcinoma. We enrolled four patients with ADPKD in Seoul National University Hospital, suffering from enlarged polycystic liver. We embolized the hepatic arteries supplying the dominant hepatic segments replaced by cysts using polyvinyl alcohol particles and micro-coils. The patients were evaluated 12 months after embolization for the change in both liver and cyst volumes. Among four patients, one patient was lost in follow up and 3 patients were included in the analysis. Both liver (33%; 10%) and cyst volume (47.7%; 11.4%) substantially decreased in two patients. Common adverse events were fever, epigastric pain, nausea, and vomiting. We suggest that TAE is effective and safe in treating symptomatic polycystic liver in selected ADPKD patients.

[1]  D. Gouma,et al.  Results of percutaneous sclerotherapy and surgical treatment in patients with symptomatic simple liver cysts and polycystic liver disease. , 2007, World journal of gastroenterology.

[2]  Y. Ubara,et al.  Percutaneous transcatheter hepatic artery embolization for liver cysts in autosomal dominant polycystic kidney disease. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  V. Torres Treatment of polycystic liver disease: one size does not fit all. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  Y. Ubara New Therapeutic Option for Autosomal Dominant Polycystic Kidney Disease Patients With Enlarged Kidney and Liver , 2006, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[5]  S. Harrison,et al.  New Advances in Evaluation and Management of Patients with Polycystic Liver Disease , 2005, The American Journal of Gastroenterology.

[6]  Y. Ubara,et al.  Intravascular embolization therapy in a patient with an enlarged polycystic liver. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  T. Robinson,et al.  Laparoscopic palliation of polycystic liver disease , 2004, Surgical Endoscopy And Other Interventional Techniques.

[8]  D. Chauveau,et al.  Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. , 2000, Journal of the American Society of Nephrology : JASN.

[9]  A. Scherzinger,et al.  Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease , 1997, Hepatology.